Loss of Pulse Detection vs Tempus ECG-AF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
VS
by Tempus AI, Inc.

AI Verdict

Tool A, Fitbit's Loss of Pulse Detection, is designed for real-time emergency response, detecting acute events like loss of pulse via a wearable and alerting emergency services. Conversely, Tool B, Tempus ECG-AF, is an AI-based algorithm for proactive risk stratification, identifying patients at risk of developing atrial fibrillation within 12 months through 12-lead ECG analysis in a clinical setting. While both are cardiology AI tools, their distinct focus areas are emergency intervention and predictive diagnostic support, respectively.

Choose Loss of Pulse Detection if…

Choose Loss of Pulse Detection if you are an individual seeking a personal safety net that can automatically detect a critical health event and summon emergency assistance. This feature is ideal for users who want real-time monitoring and immediate, automated emergency response capabilities directly from their wearable device.

View Loss of Pulse Detection →

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if you are a healthcare provider looking to proactively identify older patients at high risk of developing atrial fibrillation within the next year. This AI-powered tool is best suited for integrating into clinical workflows to enhance early detection and facilitate timely preventative interventions for eligible patients aged 65 or older.

View Tempus ECG-AF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Loss of Pulse Detection Tempus ECG-AF
Pricing Unknown Contact vendor
Deployment Unknown Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.
BAA Available Yes AI-estimated Yes AI-estimated
FDA Status Cleared AI-estimated Yes AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Loss of Pulse Detection

Tool A (Loss of Pulse Detection) is integrated into a consumer wearable device, offering automatic detection and alerts with minimal user interaction once enabled. This direct-to-consumer, passive monitoring approach makes it highly accessible and user-friendly for the average individual. Tool B (Tempus ECG-AF) requires integration into healthcare facility systems and professional interpretation, making it less directly 'usable' by an individual patient.

Clinical Value

Tempus ECG-AF

Tool B (Tempus ECG-AF) provides proactive risk prediction for a chronic and serious condition (Atrial Fibrillation) within a 12-month window, enabling earlier identification and follow-up to potentially prevent severe complications like stroke. While Tool A addresses acute, life-threatening events with immediate intervention, Tool B's focus on predictive analytics for preventative care offers significant long-term clinical value by allowing for planned medical management.

Pricing & Value

Loss of Pulse Detection

Tool A (Loss of Pulse Detection) is included as a feature with compatible devices, offering clear value to the consumer without any additional subscription or purchase cost. Tool B (Tempus ECG-AF) requires contacting the vendor for pricing, although it does have established CMS reimbursement pathways for healthcare providers. For the end-user, Tool A's 'free' inclusion with the device presents a more straightforward and accessible value proposition.

Enterprise Readiness

Tempus ECG-AF

Tool B (Tempus ECG-AF) is explicitly designed as a software solution for integration into healthcare facility systems and workflows, compatible with existing 12-lead ECG devices from major manufacturers. This makes it highly 'enterprise ready' for deployment within clinical settings. Tool A, while HIPAA compliant, is a consumer-facing feature on personal wearable devices and is not intended for enterprise-wide deployment by healthcare systems.

Innovation

Tempus ECG-AF

Both tools demonstrate innovation. Tool A innovates in real-time, acute event detection and automated emergency response using consumer wearables. However, Tool B's AI-based algorithm for predictive risk stratification of Atrial Fibrillation from standard 12-lead ECGs, trained on over 1.5 million ECGs, represents a significant advancement in leveraging AI for proactive disease management within a clinical diagnostic context.

Support & Docs

Tempus ECG-AF

As an enterprise clinical solution, Tool B (Tempus ECG-AF) inherently requires and provides comprehensive technical, clinical, and integration support, along with detailed documentation for healthcare professionals and IT teams. Tempus's website offers a document library with technical information and guidelines. Tool A, being a consumer feature, relies on general device support and user-facing help articles, which are typically less specialized than enterprise-level support.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Loss of Pulse Detection Tempus ECG-AF
Name Loss of Pulse Detection Tempus ECG-AF
Description FDA-cleared feature on compatible wearable devices that uses PPG and accelerometry to detect a potential loss of pulse and can automatically alert emergency services if the user is unresponsive. FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up.
Company Fitbit Tempus AI, Inc.
Primary Function Automatic loss of pulse detection and automated emergency service calling if unresponsive. AI-based algorithm for 12-lead ECG analysis to detect signs associated with new onset Atrial Fibrillation (AF) within 12 months.
Input/Sensor Type PPG and accelerometry sensors 12-lead ECG recordings
Target Population/Use Case Users of compatible Fitbit/Pixel devices, with an opt-in feature for user control. Patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.

Videos

Demos, reviews, and walkthroughs featuring Loss of Pulse Detection and Tempus ECG-AF.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Tool A, Fitbit's Loss of Pulse Detection, is designed for real-time emergency response by detecting a potential loss of pulse and automatically alerting emergency services if the user is unresponsive. Tool B, Tempus ECG-AF, is an AI-based algorithm that analyzes 12-lead ECGs to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter within the next 12 months, supporting earlier identification and follow-up.
Tool A utilizes photoplethysmography (PPG) and accelerometry sensors from a compatible wearable device to detect a loss of pulse. Tool B analyzes 12-lead ECG recordings to identify signs associated with new onset Atrial Fibrillation.
Tool A is an opt-in feature for users of compatible Fitbit/Pixel wearable devices, but it is not intended for individuals under 22 years of age or those with a high risk for sudden cardiac death. Tool B is specifically for patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.
If Tool A detects a loss of pulse and the user is unresponsive, it provides haptic and audio alerts and can automatically call emergency services, sharing the user's location. Tool B's results are interpreted in conjunction with other diagnostic information and clinical history to support earlier identification and follow-up for patients at increased risk of developing AF.

Backers

Who funded each tool's parent company.

Loss of Pulse Detection

AI Tool Finder
AI-powered search. Results may not be comprehensive.